Published in Cancer Weekly, April 19th, 2005
Researchers at the Medical College of Ohio Hospital are further evaluating OvaRex MAb (oregovomab), an investigational therapy, to determine the extent of remission in patients who have a favorable response to surgery and chemotherapy. They are also assessing survival, quality of life, immune response, and safety.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.